RxDoctor Payments Data

Christopher Wilson, MD

Urology · Bossier City, LANPI 1760691752

Payments from drug & device makers

$4,333in general payments, 2019–2025

Across 195 payments — averaging $22.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$522
  • Johnson & Johnson$504
  • Sun Pharmaceutical Industries Inc.$349
  • Antares Pharma, Inc.$311
  • Sumitomo Pharma America, Inc.$298
  • Procept Biorobotics Corporation$279
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$3,97892%
  • Education$3558%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,333 in reported general payments places this provider in the 60th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$319,260
Medicare patients
884
Services billed
7,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron193$125,730
MyrbetriqMirabegron94$64,103
Tamsulosin Hcl935$18,466
Alfuzosin Hcl ErAlfuzosin Hcl407$10,453
Mirabegron ErMirabegron18$9,833
Oxybutynin Chloride ErOxybutynin Chloride390$9,316
Testosterone22$8,600
Finasteride441$6,630
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst203$5,526
Fosfomycin Tromethamine13$5,176
Testosterone Cypionate80$3,702
Silodosin26$3,291
Solifenacin Succinate103$2,746
Cephalexin141$1,864
Oxybutynin Chloride102$1,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$298$125,730193 claims
Astellas Pharma US IncMyrbetriq$522$64,10394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 199 urology providers in Louisiana.

Other urology in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →